Slingshot members are tracking this event:
Theravance Biopharma (TBPH) and Celgene (CELG) initiate Phase 2a clinical trial of TD-6450 to treat patients with Hepatitis C virus
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Oct 28, 2015
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 2a, Phase 2 Clinical Trial, Hepatitis C, Td-6450